

Founded
1968

Location
Castellbisbal, Barcelona, Spain

Main Focus
CNS, Nephrology, Urology, Cardiovascular, Gastroenterology, Rheumatology/ Orthopedic, Oncology/Radiotherapy, Gynecology.

About Rubió
For more than 55 years Rubió, a family-owned company, has been recognized for the development, manufacture and marketing of medicines with high therapeutic value for specialists as well as of certain drugs for life-threatening diseases, with long expertise in niche markets.

Rubió's determination to meet the health needs of every single patient has led the company to be distinguished as per being pioneer of products targeted to low incidence diseases which affect only a small number of patients and that require the development of specific pharmaceutical products to treat them.

International Alliances and Partnering Strategy
Rubió has established a strong network of partnerships through in and out activities and commercial distribution agreements. Rubió has been in the export business since 1982 and has alliances in over 70 countries. Rubió is constantly exploring new territories and partnerships.

Contact details:

Laboratorios Rubió, S.A.
Industria 29, P.I. Comte de Sert
08755 Castellbisbal, Barcelona, Spain
Tel.: +34 937 722 509
www.laboratoriosrubio.com

Contact:
export@labrubio.com

07/2026

Hydroxychloroquine

Effective and safe treatment option in the management of Lupus & Rheumatoid arthritis



General Information

Brand:	Hydroxychloroquine Rubió®
API:	Hydroxychloroquine Sulfate
Presentation:	200 mg x 30 film-coated tablets packaged in Blisters

Indications

- Rheumatoid Arthritis (joints inflammation)
- Treatment of non-acute and non-complicate Malaria attacks and prevention of Malaria
- Systemic and discoid Lupus Erythematosus (skin or internal organs illness)

Competitive Advantages

- Coated tablets which allows better patient swallowing.
- Rubió is the leader in Spain with 95% of market share with this molecule.

Registration and Marketing Authorization

- Rubió has marketed this molecule in Spain since 2002
- To be registered as Generic of the originator (Plaquenil®, Sanofi's Reference Product). Bioequivalence (BE) study with Plaquenil® will be available in the CTD file ready in Q4 2026.
- Rubió markets this molecule in DO, ES, IQ, LB & RS.

Deal Design

- Deal design consisting of an Exclusive Licensing & Supply/Distribution Agreement to market the Finished Product manufactured by Laboratorios Rubió,S.A.
- We are searching for the best Partner to develop trustful, fruitful and long-term business partnerships.